Factors associated with treatment nonadherence among US bipolar disorder patients

Human Psychopharmacology

Volumn 23, Issue 2, 2008, Pages 95-105

  Baldessarini, Ross J ^a,c   Perry, Richard ^b   Pike, James ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ADELPHI REAL WORLD   (United Kingdom)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Adherence; Adverse effects; Bipolar disorder; Long term treatment; Maintenance; Prophylaxis

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; BIPOLAR DISORDER; BLURRED VISION; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOMANIA; JUVENILE; MAJOR CLINICAL STUDY; MALE; MANIA; MINORITY GROUP; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PATIENT SELECTION; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; RANDOM SAMPLE; RISK ASSESSMENT; SEX RATIO; SIDE EFFECT; SOMNOLENCE; TREMOR; UNITED STATES; UNIVARIATE ANALYSIS; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGE FACTORS; ALCOHOLISM; ATTITUDE OF HEALTH PERSONNEL; BIPOLAR DISORDER; FEMALE; FORECASTING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSESSIVE-COMPULSIVE DISORDER; PATIENT COMPLIANCE; PHYSICIANS; POLYPHARMACY; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 40549120316     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.908     Document Type: Article

References (69)

1. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. 2005. Long-term combination therapy vs. mono-therapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 66: 174-182.
2. Baldessarini RJ. 1994. Enhancing treatment with psychotropic medicines. Bull Menninger Clin 58: 224-241.
3. Baldessarini RJ, Tarazi FI. 2005. Pharmacotherapy of psychosis and mania. In Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York; 461-500.
4. Baldessarini RJ, Salvatore P, Totten M, et al. 2004. Morbidity from onset in first-episode bipolar I disorder patients: the International-300 study. Neuropsychopharmacology 29(Suppl 1): S88.
5. Baldessarini RJ, Tondo L, Faedda GL, et al. 2006. Latency, discontinuation, and re-use of lithium treatment. Chapter 38. In Bauer M, Grof P, Müller-Oerlinghausen B (eds). Lithium in Neuropsychiatry: The Comprehensive Guide. Taylor & Francis: London; 465-481.
6. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. 2007. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 58: 85-91.
7. Barnes NC, Williams AE. 2005. Unscheduled healthcare resource use among asthma patients receiving low-dose inhaled corticosteroids maintenance treatment. Int J Clin Pract 59: 1017-1024.
8. Byrne N, Regan C, Livingston G. 2006. Adherence to treatment in mood disorders. Curr Opin Psychiatry 19: 44-49.
9. Centorrino F, Fogarty KV, Sani G, et al. 2005. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 20: 485-492.
10. Chengappa KR, Williams P. 2005. Barriers to the effective management of bipolar disorder: survey of psychiatrists based in the UK and USA. Bipolar Disord 7(Suppl 1): 38-42.
11. Coletti DJ, Leigh E, Gallelli KA, Kafantaris V. 2005. Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15: 913-917.
12. Colom F, Vieta E, Tacchi MJ, Sanchez-Moreno J, Scott J. 2005. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 7(Suppl 5): 24-31.
13. Craig TJ, Ye Q, Bromet EJ. 2006. Mortality among first-admission psychosis patients. Compr Psychiatry 47: 246-251.
14. Danion JM, Neunreuther C, Krieger-Finance F, Imbs JL, Singer L. 1987. Compliance with long-term lithium treatment in major affective disorders. Pharmacopsychiatry 20: 230-231.
15. Dardennes R, Thuile J, Friedman S, Guelfi JD. 2006. [The costs of bipolar disorder]. Encephale 32: 18-25.
16. DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. 2007. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 164: 582-590.
17. Durrenberger S, Rogers T, Walker R, de Leon J. 1999. Economic grand rounds: the high costs of care for four patients with mania who were not compliant with treatment. Psychiatr Serv 50: 1539-1542.
18. Dutta R, Boydell J, Kennedy N, Van Os J, Fearon P, Murray RM. 2007. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol Med 37: 839-847.
19. Evans DL, Charney DS, Lewis L, et al. 2005. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58: 175-189.
20. Fakhoury WK, Wright D, Wallace M. 2001. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline. Int Clin Psychopharmacol 16: 153-162.
21. Frye MA, Ketter TA, Leverich G, et al. 2000. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9-15.
22. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. 2007. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 29: 972-984.
23. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. 2006. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 67: 1209-1218.
24. Ghaemi SN (ed.). 2002. Polypharmacy in Psychiatry. Marcel Dekker: New York.
25. Gitlin MJ, Cochran SD, Jamison KR. 1989. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 50: 127-131.
26. Gorard DA. 2006. Escalating polypharmacy. Quart J Med 99: 797-800.
27. Greenhouse WJ, Meyer B, Johnson SL. 2000. Coping and medication adherence in bipolar disorder. J Affect Disord 59: 237-241.
28. Huxley N, Baldessarini RJ. 2007. Disability and its treatment in bipolar disorder patients. Bipolar Disord 9: 183-196.
29. Huxley NA, Parikh SV, Baldessarini RJ. 2000. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harvard Rev Psychiatry 8: 126-140.
30. Jamison KR, Akiskal HS. 1983. Medication compliance in bipolar disorder patients. Psychiatr Clin North Am 6: 175-192.
31. Joffe RT, MacQueen GM, Marriott M, Trevor YL. 2004. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 6: 62-66.
32. Judd LL, Akiskal HS, Schettler PJ, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59: 530-537.
33. Keck PE, Jr, McElroy SL, Strakowski SM, et al. 1996. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 57: 292-297.
34. Keck PE, Jr, McElroy SL, Strakowski SM, Bourne ML, West SA. 1997. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 33: 87-91.
35. Kessler RC, Akiskal HS, Ames M, et al. 2007. Considering the costs of bipolar depression. Behav Health 27: 45-47.
36. Khalsa HMK, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. 2007. Suicidal events and accidents in 216 first-episode bipolar-I disorder patients: predictive factors. J Affect Disord; July e-pub ahead of print (PIMD: 17614135).
37. Kleindienst N, Greil W. 2004. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J Clin Psychiatry 65: 966-974.
38. Lecrubier Y, Perry R, Milligan G. Leeuwenkamp O, Morlock R. 2007. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey. Eur. Psychiatry 22: 371-379.
39. Lin D, Mok H, Yatham LN. 2006. Polytherapy in bipolar disorder. CNS Drugs 20: 29-42.
40. Lingam R, Scott J. 2002. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105: 164-172.
41. Maarbjerg K, Aagaard J, Vestergaard P. 1988. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for non-adherence. Pharmacopsychiatry 21: 121-125.
42. Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. 2007. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 68: 1172-1176.
43. Miklowitz DJ. 1992. Longitudinal outcome and medication non-compliance among manic patients with and without mood-incongruent psychotic features. J Nerv Ment Dis 180: 703-711.
44. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. 2002. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications]. Encephale 28: 266-272.
45. Mitchell AJ. 2007. Adherence behaviour with psychotropic medication is a form of self-medication. Med Hypotheses 68: 12-21.
46. Müller-Oerlinghausen B, Berghofer A, Ahrens B. 2003. The anti-suicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48: 433-439.
47. Osterberg L, Blaschke T. 2005. Adherence to medication. N Engl J Med 353: 487-497.
48. Pope M, Scott J. 2003. Do clinicians understand why individuals stop taking lithium? J Affect Disord 74: 287-291.
49. Post RM, Denicoff KD, Leverich G, et al. 2003. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 64: 680-690.
50. Roberts J, Williams AE. 2004. Quality-of-life and asthma control with low-dose inhaled corticosteroids. Br J Nursing 13: 1124-1129.
51. Sajatovic M, Davies M, Hrouda DR. 2004. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 55: 264-269.
52. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. 2006. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 8: 232-241.
53. Schou M. 1997. Combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 95: 361-363.
54. Schumann C, Lenz G, Berghofer A, Müller-Oerlinghausen B. 1999. Non-adherence with long-term prophylaxis: 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 89(2): 47-257.
55. Scott J, Pope M. 2002a. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 63: 384-390.
56. Scott J, Pope M. 2002b. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 159: 1927-1929.
57. Scott J, Tacchi MJ. 2002. A pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxis. Bipolar Disord 4: 386-392.
58. Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U. 2007. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther 14: 241-246.
59. Steiner JF, Earnest MA. 2000. The language of medication-taking. Ann Intern Med 132: 926-930.
60. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. 1993. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 269: 2779-2781.
61. Svarstad BL, Shireman TI, Sweeney JK. 2001. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52: 805-811.
62. Taylor MJ, Goodwin GM. 2006. Long-term prophylaxis in bipolar disorder. CNS Drugs 20: 303-310.
63. Tondo L, Isacsson G, Baldessarini R. 2003. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 17: 491-511.
64. Trauer T, Sacks T. 2000. The relationship between insight and medication adherence in severely mentally ill clients treated in the community. Acta Psychiatr Scand 102: 211-216.
65. Weisler RH. 2007. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 8: 745-758.
66. Weiss RD, Greenfield SF, Najavits L, et al. 1998. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 59: 172-174.
67. Wolff N, Perlick DA, Kaczynski R, Calabrese J, Nierenberg A, Miklowitz DJ. 2006. Modeling costs and burden of informal caregiving for persons with bipolar disorder. J Ment Health Policy Econ 9: 99-110.
68. Wyatt RJ, Henter I. 1995. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol 30: 213-219.
69. Yen CF, Chen CS, Ko CH, et al. 2005. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci 59: 403-409.